Novo Nordisk announced Tuesday it will be slashing the list price of its blockbuster GLP-1 medications, Ozempic, Wegovy and Rybelsus, by up to 50 percent beginning next year. Starting on Jan. 1, 2027, the list price for Wegovy, Ozempic and Rybelsus, Novo’s semaglutide products, will be $675 across the board in the U.S. This reduction…
Goldman Sachs Set to Move Into Credit Suisses Milan Office
...
Read moreDetails
